CoChat
Sign Up
Cited by 145Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesBipolar Disorder and Treatment

Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study

Open access
McIntyre, Alexander, Gendron, Alain, McIntyre, Amanda·2007·Depression and Anxiety
DOI 10.1002/da.20275
Open this paper in CoChat — free accountOpen PDF

Abstract

This double-blind, placebo-controlled study examined the efficacy and tolerability of quetiapine in combination with selective serotonin reuptake inhibitors (SSRIs)/venlafaxine in 58 patients with major depressive disorder, comorbid anxiety symptoms (HAM-A-14 score > or =14), and residual depressive symptoms (HAM-D-17 score > or =18, CGI-S score > or =4). Patients had received an SSRI/venlafaxine (at a predefined therapeutic dose) for > or =6 weeks. Overall, 62% (18/29) of quetiapine- and 55% (16/29) of placebo-treated patients completed the study. The mean change in HAM-D and HAM-A total scores from baseline to Week 8 (primary endpoint) was significantly greater with quetiapine (mean dose 182 mg/day) than placebo: -11.2 vs. -5.5 (P=.008) and -12.5 vs. -5.9 (P=.002), respectively. The onset of quetiapine efficacy (HAM-D/HAM-A/CGI-I) was rapid (by Week 1) and continued through to Week 8. Significant differences (P<.05) from baseline to Week 8 were observed between groups in 7/17 HAM-D (including feelings of guilt, suicide) and 6/14 HAM-A items (including tension, cardiovascular symptoms). Response (> or =50% decrease in total score) was higher for quetiapine than placebo: HAM-D, 48% vs. 28% (not significant, NS); HAM-A, 62% vs. 28% (P=.02). Remission (total score < or =7) was higher for quetiapine than placebo: HAM-D, 31% vs. 17% (NS); HAM-A, 41% vs. 17% (NS). CGI-S, CGI-I, and the Global Assessment Scale showed that quetiapine was significantly more effective than placebo. For quetiapine, adverse events (AEs) were similar to those previously observed; sedation/somnolence/lethargy was the most commonly reported. Here quetiapine was shown to be effective as augmentation of SSRI/venlafaxine therapy in patients with major depression, comorbid anxiety, and residual depressive symptoms, with no unexpected tolerability issues. Further studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.20275

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, fourth edition, text revision.
  2. Goldstein JM, Paulsson B, Sweitzer D, Zhong K. 2005. A review of the evidence for somnolence with quetiapine treatment. Abstract published online by the American Psychiatric Association (http:// www.psych.org/edu/other_res/lib_archives/archives/meetings/ AMN/2005nra.cfm) [Accessed 5 December 2006].

Cited by

Sorted by citations

Related

Authors
McIntyre, A., Gendron, A., & McIntyre, A.
Affiliations
  • Penticton Regional Hospital (CA)
  • AstraZeneca (Canada) (CA)
Corresponding author
McIntyre, Alexander
ORCID
Gendron, Alain
Venue
Depression and Anxiety
Publisher
Wiley
Published
2007
Volume
24
Issue
7
Pages
487-494
ISSN
  • 1091-4269 (ISSN-L)
  • 1520-6394
DOI
10.1002/da.20275
OpenAlex
W2065791141
Cited by
145
References
35
Citations by year
2026: 4 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 7 · 2013: 18 · 2012: 3
FWCI
5.64
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3165 d)
Locations
  • Depression and Anxiety (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
quetiapine, major depressive disorder, anxiety comorbidity, residual depressive symptoms, selective serotonin reuptake inhibitors, venlafaxine, adjunctive therapy, atypical antipsychotics, antidepressant efficacy, tolerability, adverse events, sedation, remission, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, CGI-S, CGI-I, Global Assessment Scale
MeSH terms
Quetiapine Fumarate, Venlafaxine Hydrochloride, Adult, Anxiety Disorders, Cyclohexanols, Major Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Personality Inventory, Antipsychotic Agents, Comorbidity, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review